ClinicalTrials.gg
Active, not recruitingNCT04317794STANDARDUpdated Oct 26, 2026

A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care

An observational study in Muscular Atrophy, Spinal, sponsored by Biogen. Active, not recruiting at 16 sites in South Korea. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Biogen · Observational

Updated Oct 26, 2026Title changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
74
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies in Muscular Atrophy, Spinal by Biogen — 5 open to participants now, 10 under way, 4 of them phase 3. Muscular Atrophy, Spinal · Biogen.

Started
2019
the only one that year
Observational
5 of 27
1 open now
Registered
13th of 27
by date

Among the 27 studies in Muscular Atrophy, Spinal by Biogen, this one is the only one that started in 2019, is one of 5 observational ones, and was the 13th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

5 of the 27 studies in Muscular Atrophy, Spinal by Biogen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Atrophy, Spinal by Biogen, or all of them as a file.
02

Study summary

In this study, researchers will learn more about the effects of nusinersen, also known as Spinraza®, in Korean participants with spinal muscular atrophy, also known as SMA. This is a drug available for doctors to prescribe for people with SMA. This is known as an "observational" study, which collects health information about study participants without changing their medical care.

In Korea, some medicines for rare diseases are allowed to be reviewed for up to 10 years when there are no other treatment options. This study was set up to support that review by collecting more information about nusinersen. In this study, researchers wanted to learn more about its safety and how it may help patients receiving it as part of their routine medical care in Korea.

The main goal of the study is to learn about the long-term safety of nusinersen in Korean participants with SMA. The main question researchers want to answer are:

  • How many participants have adverse events and serious adverse events during the study?

Researchers will also learn more about:

  • How does nusinersen affect the participants' muscle function and ability to move?
  • How long participants live after joining the study?
  • How many participants need help with their breathing during this study?

This study will be done as follows:

  • Participants will join the study after signing an informed consent form, also known as an ICF.
  • During the study, health information from the participants' regular visits to their doctor will be collected about every 4 months.
  • During each visit, doctors will measure the participants' motor function with different tests. They will also check the participants' overall health and ask how they are feeling.
  • Each participant will be in the study for up to 2 years.
Read the detailed description

The primary objective is to evaluate the safety of nusinersen sodium injection in the postmarketing setting in Korea. The secondary objective is to evaluate the effectiveness of nusinersen sodium injection in the postmarketing setting in Korea.

03

Conditions studied

  • Muscular Atrophy, Spinal
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants who are receiving or about to initiate treatment with commercial Spinraza in Korea according to the local marketing authorization (including documentation of SMA diagnosis), agree to the collection and use of data as specified in the protocol, and meet the eligibility criteria.

Eligibility criteria

Key Inclusion Criteria:

  • Currently receiving or about to initiate treatment with commercial Spinraza in the postmarketing setting
  • Genetic documentation of 5q-linked SMA

Key Exclusion Criteria:

  • to the active substance or any of the of Spinraza
  • Ongoing participation or participation within 6 months or 5 half-lives of the agent (whichever is longer) of enrollment in other interventional clinical trials for the treatment of SMA
  • Inability to comply with study requirements

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
74 participants (actual)
Patient registry
No

Groups and cohorts

  • All Participants

    Participants who were prescribed with nusinersen sodium injection (12 mg or 50/28 mg regimens) in Korea according to local marketing authorization.

    Drug: Nusinersen Sodium Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is a medically important event.

    Time frame: Up to End of Treatment (2 Years)

Secondary outcomes

  1. Change from Baseline in Hammersmith Infant Neurological Examination (HINE) Section 2 Scores

    Section 2 of the HINE is used to assess motor milestones of the participants. It is composed of 8 motor milestone categories: voluntary grasp, ability to kick in supine position, head control, rolling, sitting, crawling, standing, and walking.

    Time frame: Baseline, up to End of Treatment (2 years)

  2. Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)

    The HFMSE is a tool used to assess motor function in children with SMA. The original 20 item Hammersmith Functional Motor Scale (HFMS) was expanded to include 13 additional items to improve sensitivity for the higher functioning ambulant population. Participants are asked to complete a specific movement and are then graded on the quality and execution of that movement. Higher scores indicate higher levels of motor ability where 0=unable, 1=performed with some assistance, and 2=unaided. The overall score is the sum of the scores for all activities.

    Time frame: Baseline, up to End of Treatment (2 years)

  3. Time to Death

    Time frame: Up to End of Treatment (2 years)

  4. Number of Participants with Ventilatory Support

    Time frame: Up to End of Treatment (2 years)

07

Study locations

16 sites
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Feb 2027, 91 months after the start.

Of 58 observational studies under Muscular Atrophy, Spinal, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 36. This study's planned 91 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2020
First posted
Mar 23, 2020
StartActual
Jul 2, 2019
Primary completionEst.
Feb 5, 2027
CompletionEst.
Feb 5, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameChange from Baseline in Hammersmith Infant Neurological Examination (HINE) Section 2 ScoresBaseline, Day 63 and Approximately Every 4 Months Up to End of Treatment (2 years) → Baseline, up to End of Treatment (2 years)
  • Time frameChange from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)Baseline, Day 63 and Approximately Every 4 Months Up to End of Treatment (2 years) → Baseline, up to End of Treatment (2 years)
Oct 26, 2026
Title
Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)→A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Secondary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameChange from Baseline in Hammersmith Infant Neurological Examination (HINE) Section 2 ScoresBaseline, Day 63 and Approximately Every 4 Months Up to End of Treatment (2 years) → Baseline, up to End of Treatment (2 years)
    • Time frameChange from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE)Baseline, Day 63 and Approximately Every 4 Months Up to End of Treatment (2 years) → Baseline, up to End of Treatment (2 years)
    Title Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)→A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04317794
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Mar 23, 2020
Start date
Jul 2, 2019
Primary completion
Feb 5, 2027 (estimated)
Completion
Feb 5, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion